Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FWY003 · 1 trial · 1 indication
To evaluate the dose response relationship of FWY003 on GA lesion area in the study eye in participants with GA secondary to age-related macular degeneration (AMD).
| Arm | Type | Description |
|---|---|---|
| FWY003 dose level 1 | EXPERIMENTAL | Participants will receive FWY003 dose level 1 |
| FWY003 dose level 2 | EXPERIMENTAL | Participants will receive FWY003 dose level 2 |
| FWY003 dose level 3 | EXPERIMENTAL | Participants will receive FWY003 dose level 3 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo |
| Name | Type | Description |
|---|---|---|
| FWY003 | DRUG | FWY003 arm participants will receive a specific dose of FWY003 |
| Placebo | DRUG | Placebo arm participants will receive placebo |
Inclusion Criteria: Male or female participants ≥ 50 years of age. * A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye. 1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), ...
FWY003 is being developed for geographic atrophy secondary to age-related macular degeneration, an advanced form of dry AMD that causes progressive loss of central vision. It is an investigational small molecule in Phase 2 testing and is not yet available as a treatment outside of clinical trials.
FWY003 is being developed by Novartis AG, which trades under the ticker NVS. Novartis is sponsoring the clinical program evaluating FWY003 in geographic atrophy secondary to age-related macular degeneration, an ophthalmology indication.
FWY003 is in Phase 2 clinical development. It is an investigational small molecule and has not been approved by the FDA for any use. The Phase 2 program is currently recruiting participants with geographic atrophy secondary to age-related macular degeneration.
FWY003 is being studied in NCT07441642, a Phase 2 trial comparing FWY003 with placebo in participants with geographic atrophy secondary to age-related macular degeneration. The trial is recruiting and plans to enroll 272 participants across sites in the United States, Europe, Asia, Latin America, Australia, and Canada.
NCT07441642 is a randomized, double-blind, placebo-controlled Phase 2 trial of FWY003 in geographic atrophy secondary to age-related macular degeneration. It plans to enroll 272 participants aged 50 years and older of all sexes, and it is currently recruiting across 19 countries and territories.